307 related articles for article (PubMed ID: 30593615)
1. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus.
Li DK; Chung RT
Methods Mol Biol; 2019; 1911():3-32. PubMed ID: 30593615
[TBL] [Abstract][Full Text] [Related]
2. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
3. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms associated with resistance to protease inhibitors in naïve patients infected with hepatitis C virus genotype 1 in Argentina: Low prevalence of Q80K.
Martínez AP; Culasso ACA; Pérez PS; Romano V; Campos RH; Ridruejo E; García G; Di Lello FA
Virus Res; 2017 Aug; 240():140-146. PubMed ID: 28837817
[TBL] [Abstract][Full Text] [Related]
5. Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use.
Bagaglio S; Uberti-Foppa C; Morsica G
Drugs; 2017 Jul; 77(10):1043-1055. PubMed ID: 28497432
[TBL] [Abstract][Full Text] [Related]
6. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection.
Esposito I; Marciano S; Haddad L; Galdame O; Franco A; Gadano A; Flichman D; Trinks J
Viruses; 2018 Dec; 11(1):. PubMed ID: 30577623
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus early kinetics and resistance-associated substitution dynamics during antiviral therapy with direct-acting antivirals.
Perpiñán E; Caro-Pérez N; García-González N; Gregori J; González P; Bartres C; Soria ME; Perales C; Lens S; Mariño Z; Londoño MC; Ariza X; Koutsoudakis G; Quer J; González-Candelas F; Forns X; Pérez-Del-Pulgar S
J Viral Hepat; 2018 Dec; 25(12):1515-1525. PubMed ID: 30141252
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of naturally occurring amino acid substitutions associated with resistance to hepatitis C virus NS3/NS4A protease inhibitors in São Paulo state.
Moreira RC; de Torres Santos AP; Lisboa-Neto G; Mendes-Corrêa MCJ; Lemos MF; Malta FM; Santana RAF; Dastoli GTF; de Castro VFD; Pinho JRR
Arch Virol; 2018 Oct; 163(10):2757-2764. PubMed ID: 29961118
[TBL] [Abstract][Full Text] [Related]
10. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
[TBL] [Abstract][Full Text] [Related]
11. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness.
Guo M; Lu J; Gan T; Xiang X; Xu Y; Xie Q; Zhong J
Antiviral Res; 2019 Nov; 171():104612. PubMed ID: 31542377
[TBL] [Abstract][Full Text] [Related]
12. Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype.
Morsica G; Vercesi R; Hasson H; Messina E; Uberti-Foppa C; Bagaglio S
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452351
[TBL] [Abstract][Full Text] [Related]
13. Challenge to overcome: Nonstructural protein 5A-P32 deletion in direct-acting antiviral-based therapy for hepatitis C virus.
Sato K; Uraoka T
World J Gastroenterol; 2018 Oct; 24(38):4304-4310. PubMed ID: 30344416
[TBL] [Abstract][Full Text] [Related]
14. Antiviral resistance and direct-acting antiviral agents for HCV.
Aloia AL; Locarnini S; Beard MR
Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
[TBL] [Abstract][Full Text] [Related]
15. The Role of RASs /RVs in the Current Management of HCV.
Malandris K; Kalopitas G; Theocharidou E; Germanidis G
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696525
[TBL] [Abstract][Full Text] [Related]
16. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA;
J Viral Hepat; 2017 Jan; 24(1):37-42. PubMed ID: 27666440
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of pre-treatment hepatitis C virus NS5A resistance associated amino-acid substitutions in genotype 1A infected patients in Scotland.
Bradley-Stewart A; Goldstein E; MacLean A; Gunson R
J Clin Virol; 2018 Apr; 101():44-46. PubMed ID: 29414187
[TBL] [Abstract][Full Text] [Related]
18. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance.
Khan S; Soni S; Veerapu NS
Front Cell Infect Microbiol; 2020; 10():325. PubMed ID: 32714881
[TBL] [Abstract][Full Text] [Related]
19. Resistance to DAAs: When to Look and When It Matters.
Wyles DL
Curr HIV/AIDS Rep; 2017 Dec; 14(6):229-237. PubMed ID: 29116550
[TBL] [Abstract][Full Text] [Related]
20. Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.
Harrington PR; Komatsu TE; Deming DJ; Donaldson EF; O'Rear JJ; Naeger LK
Hepatology; 2018 Jun; 67(6):2430-2448. PubMed ID: 29194682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
